Trial Profile
Nivolumab and Ipilimumab and Radiation Therapy in Microsatellite Stable (MSS) and Microsatellite Instability (MSI) High Colorectal and Pancreatic Cancer
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 12 Sep 2022
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Adenocarcinoma; Colorectal cancer; Pancreatic cancer
- Focus Therapeutic Use
- 07 Sep 2022 Planned End Date changed from 31 Oct 2026 to 1 Oct 2026.
- 07 Sep 2022 Planned primary completion date changed from 31 Jul 2022 to 1 Jul 2024.
- 24 Mar 2021 Planned End Date changed from 31 Oct 2025 to 31 Oct 2026.